Terms: = Breast cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
44 results:
1. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
Shuaib M; Chaudhri S; Kumar S
Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
[TBL] [Abstract] [Full Text] [Related]
2. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F; Stevens LE; Li Z; Brock JE; Gulvady A; Huang Y; Nakhlis F; Patel A; Force JM; Haddad TC; Ueno N; Stearns V; Wolff AC; Clark AS; Bellon JR; Richardson ET; Balko JM; Krop IE; Winer EP; Lange P; Hwang ES; King TA; Tolaney SM; Thompson A; Gupta GP; Mittendorf EA; Regan MM; Overmoyer B; Polyak K
Breast Cancer Res; 2024 Jan; 26(1):20. PubMed ID: 38297352
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative breast cancer.
Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
[TBL] [Abstract] [Full Text] [Related]
4. SKAP1 Is a Novel Biomarker and Therapeutic Target for Gastric cancer: Evidence from Expression, Functional, and Bioinformatic Analyses.
Zhu L; Yu Q; Li Y; Zhang M; Peng Z; Wang S; Quan Z; Gao D
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511629
[TBL] [Abstract] [Full Text] [Related]
5. CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.
Wu L; Sun S; Qu F; Sun M; Liu X; Sun Q; Cheng L; Zheng Y; Su G
Cancer Immunol Immunother; 2023 Jun; 72(6):1479-1492. PubMed ID: 36472587
[TBL] [Abstract] [Full Text] [Related]
6. Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative breast cancer.
Peng P; Qiang X; Li G; Li L; Ni S; Yu Q; Sourd L; Marangoni E; Hu C; Wang D; Wu D; Wu F
Mol Cancer Ther; 2023 Feb; 22(2):205-214. PubMed ID: 36223547
[TBL] [Abstract] [Full Text] [Related]
7. Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.
Malash I; Mansour O; Gaafar R; Shaarawy S; Abdellateif MS; Ahmed OS; Zekri AN; Bahnassy A
J Egypt Natl Canc Inst; 2022 Jul; 34(1):31. PubMed ID: 35871690
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
[TBL] [Abstract] [Full Text] [Related]
9. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract] [Full Text] [Related]
10. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National cancer Database analysis.
Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I
Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of Novel Pyrrolo[2,3-
Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
[TBL] [Abstract] [Full Text] [Related]
12. Phase I study of jak1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Lynce F; Williams JT; Regan MM; Bunnell CA; Freedman RA; Tolaney SM; Chen WY; Mayer EL; Partridge AH; Winer EP; Overmoyer B
Cancer Chemother Pharmacol; 2021 May; 87(5):673-679. PubMed ID: 33585999
[TBL] [Abstract] [Full Text] [Related]
13. Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.
Tripolt S; Neubauer HA; Knab VM; Elmer DP; Aberger F; Moriggl R; Fux DA
Neoplasia; 2021 Feb; 23(2):270-279. PubMed ID: 33465556
[TBL] [Abstract] [Full Text] [Related]
14. Identifying intracellular signaling modules and exploring pathways associated with breast cancer recurrence.
Chen X; Gu J; Neuwald AF; Hilakivi-Clarke L; Clarke R; Xuan J
Sci Rep; 2021 Jan; 11(1):385. PubMed ID: 33432018
[TBL] [Abstract] [Full Text] [Related]
15. Overexpression of miR-1225 promotes the progression of breast cancer, resulting in poor prognosis.
Gao S; Shi P; Tian Z; Yang X; Liu N
Clin Exp Med; 2021 May; 21(2):287-296. PubMed ID: 33423149
[TBL] [Abstract] [Full Text] [Related]
16. Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan.
Konishi T; Fujiogi M; Michihata N; Morita K; Matsui H; Fushimi K; Tanabe M; Seto Y; Yasunaga H
Breast Cancer Res Treat; 2021 Jan; 185(1):175-182. PubMed ID: 32949351
[TBL] [Abstract] [Full Text] [Related]
17. 10,11-dehydrocurvularin exerts antitumor effect against human breast cancer by suppressing STAT3 activation.
Zhao Q; Bi Y; Zhong J; Li X; Guo J; Liu YX; Pan LR; Tan Y; Deng ZS; Yu XJ
Acta Pharmacol Sin; 2021 May; 42(5):791-800. PubMed ID: 32868906
[TBL] [Abstract] [Full Text] [Related]
18. Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling.
Yang H; Geng YH; Wang P; Yang H; Zhou YT; Zhang HQ; He HY; Fang WG; Tian XX
Oncogene; 2020 Aug; 39(35):5795-5810. PubMed ID: 32724162
[TBL] [Abstract] [Full Text] [Related]
19. Adipose Tissue-Derived Mesenchymal Stem Cells Suppress Growth of Huh7 Hepatocellular Carcinoma Cells via Interferon (IFN)-β-Mediated JAK/STAT1 Pathway
Byun CS; Hwang S; Woo SH; Kim MY; Lee JS; Lee JI; Kong JH; Bae KS; Park IH; Kim SH; Eom YW
Int J Med Sci; 2020; 17(5):609-619. PubMed ID: 32210710
[TBL] [Abstract] [Full Text] [Related]
20. Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma.
Yang MH; Jung SH; Chinnathambi A; Alahmadi TA; Alharbi SA; Sethi G; Ahn KS
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878046
[TBL] [Abstract] [Full Text] [Related]
[Next]
